Arcturus Therapeutics Holdings (ARCT) Financials
ARCT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 429.4 million | 150.9 million |
2023-09-30 | 457.7 million | 177.6 million |
2023-06-30 | 430.6 million | 145.5 million |
2023-03-31 | 470.9 million | 141.6 million |
ARCT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -1.4 million | 8.8 million |
2023-09-30 | -33.4 million | 9.3 million |
2023-06-30 | 50.5 million | 8.4 million |
2023-03-31 | -36.6 million | 8.2 million |
ARCT Net Income
No data available :(
ARCT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 347.0 million | - | 30.2 million |
2023-09-30 | 311.9 million | - | 27.0 million |
2023-06-30 | 323.5 million | - | 32.2 million |
2023-03-31 | 327.9 million | - | 29.2 million |
ARCT Shares Outstanding
ARCT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 837076 | 26.8 million | 12.5 million | 815000 |
2023-09-30 | 981000 | 51.1 million | 13.4 million | - |
2023-06-30 | 354000 | 52.7 million | 13.2 million | - |
2023-03-31 | 691000 | 51.8 million | 13.8 million | - |
ARCT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 28.2 million | 815000 |
2023-09-30 | 43.4 million | 800000 |
2023-06-30 | 9.6 million | 52.7 million |
2023-03-31 | 79.7 million | 51.8 million |
ARCT
Price: $26.55
52 week price:
Earnings Per Share: -1.12 USD
P/E Ratio: 10.54
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 359653
Ebitda: -2.9 millionMarket Capitalization: 860.5 million
Average Dividend Frequency: 1